TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.

  TAK-733 is highly potent and selective MEK allosteric site inhibitor with IC50 of 3.2 nM. TAK-733 shows potent enzymatic and cell activity with an EC50 of 1.9 nM against ERK phosphorylation in cells. [1]

 TAK-733 demonstrates broad antitumor activity in mouse xenograft models of human cancer including models of melanoma, colorectal, NSCLC, pancreatic and breast cancer. TAK-733 is well tolerated with pharmacokinetics and pharmacodynamics that support once-daily oral dosing in humans. [1] TAK-733 shows maximally efficacious doses at once daily orally doses of 10 mg/kg. [2]

 

References

[1] Qing Dong, et al. Bioorg Med Chem Lett, 2011, 21(5), 1315-1319.

[2] Fabrey R, et al. AACR Annual Meeting, 2012, Abs 3739.

转载本文请联系原作者获取授权，同时请注明本文来自陈达科学网博客。
链接地址：https://blog.sciencenet.cn/blog-2321593-932071.html

上一篇：AZD1480 is a novel ATP-competitive JAK2 inhibitor
下一篇：Trametinib (GSK1120212) is a highly specific and potent MEK1